Topic desk · 2 reviewed briefs
Bone and tissue peptide medicines
Keep osteoporosis fracture prevention separate from acute healing, athletic recovery, and healthy-person enhancement.
Evidence boundary
Bone-anabolic pharmacology does not guarantee faster healing in every fracture setting or justify performance use.
- Reviewed briefs
- 2
- Established contexts
- 2
- Reviewed claims
- 6
Before accepting a claim
Ask the question the promotion leaves out.
- 01
Was the outcome fracture prevention, bone density, or acute fracture healing?
- 02
Which high-risk osteoporosis population was enrolled?
- 03
Does the claim preserve label warnings and duration limits?
Connected briefs
Compare evidence without flattening it.
Approved human outcomesEstablished for reviewed context
Teriparatide
An established bone-anabolic peptide medicine with fracture-prevention evidence that should not be generalized to every healing claim.
3 reviewed claims · Open brief ↗Approved human outcomesEstablished for reviewed context
Abaloparatide
An approved bone-anabolic peptide with fracture outcome evidence in defined osteoporosis populations and product-specific safety limits.
3 reviewed claims · Open brief ↗